A GLP-1R agonist
Technical Support & Resources

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

Lotiglipron (hydrochloride)

Item No. 41227

Technical Information
Formal Name
2-((4-((S)-2-(5-chloropyridin-2-yl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((S)-oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid, monohydrochloride
Synonyms
  • PF-07081532
Molecular Formula
C31H31ClN4O5 • HCl
Formula Weight
Purity
≥95%
Formulation
A solid
DMSO: Slightly soluble: 0.1-1 mg/mlEthanol: Slightly soluble: 0.1-1 mg/ml
SMILES
C[C@@]1(C2=CC=C(Cl)C=N2)OC3=C(C4CCN(CC4)CC(N(C5=C6)C[C@H]7OCC7)=NC5=CC=C6C(O)=O)C=CC=C3O1.Cl
InChi Code
InChI=1S/C31H31ClN4O5.ClH/c1-31(27-8-6-21(32)16-33-27)40-26-4-2-3-23(29(26)41-31)19-9-12-35(13-10-19)18-28-34-24-7-5-20(30(37)38)15-25(24)36(28)17-22-11-14-39-22;/h2-8,15-16,19,22H,9-14,17-18H2,1H3,(H,37,38);1H/t22-,31-;/m0./s1
InChi Key
DQSGCXWSRRDBBP-ZKXIHYOGSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

    Add

    Add

    Add

    Add

    Product Description

    Lotiglipron is a glucagon-like peptide 1 receptor (GLP-1R) agonist.1 It induces cAMP accumulation in cells expressing human GLP-1R (EC50 = 0.96 nM).

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Bessire, A.J., Edmonds, D.J., Griffith, D.A., et alMetabolites of GLPIR agonists. New York, NY (2022).